Given the current interest in blockade of extracellular proteins involved in host–tumour communications as possible new therapies for triple-negative breast cancer [53,54], it will be of future interest to extend this study to secreted products of human cancer-associated fibroblasts and to identify the secreted proteins that are altered under conditions of PDIA3 ablation. This evidence concerns the gene PDIA3 and triple-negative breast carcinoma.